<div id="readability-page-1"><p>In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Immunic, with a price target of <span id="expert-recommendation-target">$8.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, Caufield is a 5-star analyst with an average return of <span>16.9%</span> and a 46.95% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Immunic, Opus Genetics, and LENZ Therapeutics.</p> <p>Immunic has an analyst consensus of Strong Buy, with a price target consensus of $4.25.</p></div>

IMUX

<p>H.C. Wainwright's Matthew Caufield reiterated a Buy rating on Immunic (IMUX) with a price target of $8.00. Caufield, a 5-star analyst with a 16.9% average return, focuses on the Healthcare sector. Immunic has a Strong Buy consensus with a $4.25 price target consensus.</p>

H.C. Wainwright Remains a Buy on Immunic (IMUX)